AU Patent

AU2023204098A1 — Dosage regimen of an S1P receptor modulator

Assigned to Novartis AG · Expires 2023-07-13 · 3y expired

What this patent protects

H:\,rsntnvoven\NRPonr blDCC\RXS\50572231.do.-9/04/2O13 Abstract S1P receptor modulators are administered following a dosage regimen providing a positive benefit-risk profile.

USPTO Abstract

H:\,rsntnvoven\NRPonr blDCC\RXS\50572231.do.-9/04/2O13 Abstract S1P receptor modulators are administered following a dosage regimen providing a positive benefit-risk profile.

Drugs covered by this patent

fingolimod-hydrochloride (FINGOLIMOD HYDROCHLORIDE)

Patent Metadata

Patent number: AU2023204098A1
Jurisdiction: AU
Classification: —
Expires: 2023-07-13
Drug substance claim: No
Drug product claim: No
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.